KLA CORP KLAC
Nasdaq · XNAS · stock · Optical Instruments & Lenses
Chart by TradingView
8/9
Piotroski F — financial health
—
Altman Z″ — distress risk
22.3%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $12.2B | $4.1B | — | $3.7B | $4.7B |
| 2024 | $9.8B | $2.8B | — | $3.0B | $3.4B |
| 2023 | $10.5B | $3.4B | — | $3.3B | $2.9B |
| 2022 | $9.2B | $3.3B | — | $3.0B | $1.4B |
| 2021 | $6.9B | $2.1B | — | $2.0B | $3.4B |
| 2020 | $5.8B | $1.2B | — | $1.6B | $2.7B |
Why these scores methodology →
Piotroski F-score: 8/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0000319201 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.